

Heather Payne

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1493778/publications.pdf>

Version: 2024-02-01

40
papers

802
citations

687363

13
h-index

501196

28
g-index

40
all docs

40
docs citations

40
times ranked

1351
citing authors

#	ARTICLE	IF	CITATIONS
1	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. <i>Lancet, The</i> , 2020, 396, 1413-1421.	13.7	226
2	Management of Prostate Cancer in Elderly Patients: Recommendations of a Task Force of the International Society of Geriatric Oncology. <i>European Urology</i> , 2017, 72, 521-531.	1.9	174
3	Impact of ⁶⁸ Ga-Prostate-Specific Membrane Antigen PET/CT on Prostate Cancer Management. <i>Journal of Nuclear Medicine</i> , 2018, 59, 89-92.	5.0	58
4	Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 593-601.	1.6	38
5	National Population-Based Study Comparing Treatment-Related Toxicity in Men Who Received Intensity Modulated Versus 3-Dimensional Conformal Radical Radiation Therapy for Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1253-1260.	0.8	38
6	Patient-reported outcomes in metastatic castration-resistant prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 643-650.	27.6	27
7	Public reporting of outcomes in radiation oncology: the National Prostate Cancer Audit. <i>Lancet Oncology, The</i> , 2021, 22, e207-e215.	10.7	20
8	National cohort study comparing severe medium-term urinary complications after robot-assisted vs laparoscopic vs retropubic open radical prostatectomy. <i>BJU International</i> , 2018, 121, 445-452.	2.5	18
9	Impact of cancer service centralisation on the radical treatment of men with high-risk and locally advanced prostate cancer: A national cross-sectional analysis in England. <i>International Journal of Cancer</i> , 2019, 145, 40-48.	5.1	16
10	Identifying skeletal-related events for prostate cancer patients in routinely collected hospital data. <i>Cancer Epidemiology</i> , 2019, 63, 101628.	1.9	15
11	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018, 4, 235-244.	3.1	14
12	Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England. <i>Journal of Clinical Oncology</i> , 2020, 38, 744-752.	1.6	14
13	A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE. <i>International Journal of Cancer</i> , 2022, 150, 837-846.	5.1	14
14	Management of locally advanced prostate cancer. <i>Asian Journal of Andrology</i> , 2009, 11, 81-87.	1.6	13
15	Impact of High-Dose-Rate and Low-Dose-Rate Brachytherapy Boost on Toxicity, Functional and Cancer Outcomes in Patients Receiving External Beam Radiation Therapy for Prostate Cancer: A National Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1219-1229.	0.8	13
16	Imputation of missing prostate cancer stage in English cancer registry data based on clinical assumptions. <i>Cancer Epidemiology</i> , 2019, 58, 44-51.	1.9	11
17	Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes. <i>BJU International</i> , 2022, 130, 84-91.	2.5	11
18	Management of Node-Positive Bladder Cancer After Neoadjuvant Chemotherapy and Radical Cystectomy: A Survey of Current UK Practice. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e153-e158.	1.9	10

#	ARTICLE	IF	CITATIONS
19	Quantifying severe urinary complications after radical prostatectomy: the development and validation of a surgical performance indicator using hospital administrative data. <i>BJU International</i> , 2017, 120, 219-225.	2.5	10
20	Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1196-1203.	0.8	10
21	Treatment-related toxicity in men who received Intensity-modulated versus 3D-conformal radiotherapy after radical prostatectomy: A national population-based study. <i>Radiotherapy and Oncology</i> , 2018, 128, 357-363.	0.6	9
22	Magnetic Resonance Imaging and Targeted Biopsies Compared to Transperineal Mapping Biopsies Before Focal Ablation in Localised and Metastatic Recurrent Prostate Cancer After Radiotherapy. <i>European Urology</i> , 2022, 81, 598-605.	1.9	9
23	Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK. <i>European Journal of Cancer Care</i> , 2019, 28, e13140.	1.5	7
24	Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study. <i>Radiotherapy and Oncology</i> , 2021, 155, 48-55.	0.6	6
25	Determinants of variation in radical local treatment for men with high-risk localised or locally advanced prostate cancer in England. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 257-263.	3.9	6
26	Comparison of the risk of cardiovascular events and death in patients treated with degarelix compared with LHRH agonists. <i>Journal of Clinical Oncology</i> , 2013, 31, 42-42.	1.6	4
27	Measuring testosterone and testosterone replacement therapy in men receiving androgen deprivation therapy for prostate cancer: A survey of UK urologists' opinions and practice. <i>International Journal of Clinical Practice</i> , 2019, 73, 1-6.	1.7	3
28	Comparison of the treatment of men with prostate cancer between the US and England: an international population-based study. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 287-292.	3.9	3
29	RADIATION IN HIGH-RISK PROSTATE CANCER: HOW MUCH IS ENOUGH?. <i>BJU International</i> , 2008, 102, 663-665.	2.5	1
30	Second-line chemotherapy for advanced bladder cancer: A survey of current UK practice. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e11-52.e17.	1.6	1
31	Rectal spacers in patients with prostate cancer undergoing radiotherapy: A survey of UK urologists. <i>International Journal of Clinical Practice</i> , 2021, 75, e14338.	1.7	1
32	Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. <i>Clinical Genitourinary Cancer</i> , 2022, , .	1.9	1
33	Interventions for obstructive uropathy in advanced prostate cancer: a population-based study. <i>BJU International</i> , 2022, , .	2.5	1
34	Easing the journey through prostate cancer. <i>British Journal of Health Care Management</i> , 2010, 16, 129-133.	0.2	0
35	Anorectal toxicity of external beam radiotherapy in the treatment of prostate cancer. <i>Journal of Clinical Urology</i> , 2014, 7, 185-189.	0.1	0
36	Advances in advanced prostate cancer – the continuing journey. <i>BJU International</i> , 2016, 118, 17-19.	2.5	0

#	ARTICLE	IF	CITATIONS
37	Re: David W. Donnelly, Anna Gavin, Amy Downing, et al. Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. Eur Urol 2019;76:228â€“37. European Urology, 2020, 77, e65.	1.9	0
38	Use of bisphosphonates and other bone supportive agents in the management of prostate cancerâ€”A UK perspective. International Journal of Clinical Practice, 2020, 74, e13611.	1.7	0
39	Management of newly diagnosed metastatic hormoneâ€sensitive prostate cancer: A survey of UK Uroâ€oncologists. International Journal of Clinical Practice, 2021, 75, e13874.	1.7	0
40	Current management and proposal for guidance of radiation cystitis (RC): Results of a British Uro-oncology Group (BUG) survey.. Journal of Clinical Oncology, 2013, 31, 297-297.	1.6	0